These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30536154)

  • 1. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
    Shaik N; Hee B; Wei H; LaBadie RR
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
    Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
    Shaik MN; Hee B; Wei H; LaBadie RR
    Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
    Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
    J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.
    Shaik N; Hee B; Liang Y; LaBadie RR
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):895-902. PubMed ID: 30977980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
    Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Bioequivalence, and Safety Studies of Pantoprazole Sodium Enteric-Coated Tablets in Healthy Subjects.
    Chen Z; Gan F; Rao X; Huang X; Chen H
    Clin Pharmacol Drug Dev; 2021 May; 10(5):502-509. PubMed ID: 33128847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of rabeprazole granules versus tablets, and the effect of food on the pharmacokinetics of rabeprazole granules in healthy adults-cross-study comparison.
    Thyssen A; Solanki B; Gonzalez M; Leitz G; Treem W; Mannaert E
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):406-16. PubMed ID: 27129014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
    Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
    Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
    Shaik MN; LaBadie RR; Rudin D; Levin WJ
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects.
    Harada A; Ikushima I; Haranaka M; Yanagihara A; Nakayama D
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):249-258. PubMed ID: 31667735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
    Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
    BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.
    Moore KH; Shaw S; Laurent AL; Lloyd P; Duncan B; Morris DM; O'Mara MJ; Pakes GE
    J Clin Pharmacol; 1999 Jun; 39(6):593-605. PubMed ID: 10354963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies.
    Manitpisitkul P; Shalayda K; Russell L; Sanga P; Williams Y; Solanki B; Caruso J; Moyer JA
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):699-711. PubMed ID: 29125700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.
    Verheijen RB; van der Biessen DAJ; Hotte SJ; Siu LL; Spreafico A; de Jonge MJA; Pronk LC; De Vos FYFL; Schnell D; Hirte HW; Steeghs N; Lolkema MP
    Target Oncol; 2019 Feb; 14(1):67-74. PubMed ID: 30742245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
    Godfrey AR; Digiacinto J; Davis MW
    Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.